Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. [electronic resource]
Producer: 20090217Description: 2020-5 p. digitalISSN:- 1569-8041
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Breast Neoplasms -- drug therapy
- Clinical Trials as Topic
- Cyclophosphamide -- administration & dosage
- Doxorubicin
- Epirubicin -- administration & dosage
- Female
- Fluorouracil -- administration & dosage
- Humans
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm, Residual -- prevention & control
- Neoplasms, Hormone-Dependent -- drug therapy
- Paclitaxel -- administration & dosage
- Randomized Controlled Trials as Topic
- Receptor, ErbB-2 -- biosynthesis
- Receptors, Estrogen -- metabolism
- Receptors, Progesterone -- metabolism
- Trastuzumab
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.